Target intelligence / Profile preview

Ebola virus protein 24 (VP24)

Target
VP24
Molecular classification
Viral structural protein, Viral matrix protein, Nucleocapsid-associated protein, Other
01

Overview

Ebola virus protein 24 (VP24) is a multifunctional viral secondary matrix protein found in ebolaviruses. VP24 plays a critical role in virus assembly, nucleocapsid formation, and in suppressing the host innate immune response. It directly binds to karyopherin-α, thereby blocking the nuclear import of phosphorylated STAT1, an essential transcription factor in interferon signaling, and thus enables the virus to evade the host immune system[6][4]. VP24 is structurally distinct with a novel pyramidal or β–barrel fold, and is essential for the formation of functional, infectious viral particles and nucleocapsids[2][3][4][6]. It interacts with other viral and host proteins involved in nuclear membrane function and intracellular transport, further facilitating viral replication and egress[2][5][6]. VP24 is a promising target for antiviral research and structural studies have informed potential drug and neutralizing antibody design[4][6]. There are no approved drugs that specifically target VP24, but its central roles in infection and immune evasion make it of high therapeutic interest. If you are referring to a "VP24" from a non-Ebola or non-filovirus virus (for example, White spot syndrome virus in shrimp, also named VP24), let me know—the structure and function would be distinct[1].

Other names
Ebola VP24eVP24Viral protein 24VP24 matrix protein
02

Mechanism of action

Inhibition of STAT1-mediated interferon signaling by blocking karyopherin-α binding; Disruption of nuclear import of immune signaling proteins; Antagonism of host innate immunity.

03

Biological functions

Virus assemblyNucleocapsid formationImmune response suppressionInhibition of interferon signalingIntracellular transport of viral componentsOther
04

Disease associations

Infection
05

Safety considerations

Immune suppression leading to high pathogenicityPotential for viral pathogenesis in infected hostsContribution to severe disease phenotypes in Ebola virus infection

Beyond the preview

Go deeper on Ebola virus protein 24 (VP24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebola virus protein 24 (VP24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call